These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2908706)

  • 21. Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat.
    Coward DM
    Psychopharmacology (Berl); 1982; 78(2):180-4. PubMed ID: 6129672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supersensitivity of d-amphetamine-induced hyperthermia in rats following continuous treatment with neuroleptics.
    Norman AB; Wylie GL; Prince AK
    Eur J Pharmacol; 1987 Aug; 140(3):349-51. PubMed ID: 2888671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves.
    Drucker GE; Ritzmann RF; Wichlinski LJ; Engh K; Gordon JH; Fields JZ
    Pharmacol Biochem Behav; 1994 Jan; 47(1):141-5. PubMed ID: 8115415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity.
    Marin C; Tolosa E
    Neuropharmacology; 1997 Aug; 36(8):1115-7. PubMed ID: 9294977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
    Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates.
    Stinus L; Winnock M; Kelley AE
    Psychopharmacology (Berl); 1985; 85(3):323-8. PubMed ID: 2860688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.
    Ohno Y; Ishida K; Ishibashi T; Ikeda K; Kato T; Nakamura M
    Gen Pharmacol; 1995 May; 26(3):489-94. PubMed ID: 7789721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
    Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
    Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pertussis toxin on behavioral responses during different withdrawal periods from chronic cocaine treatment.
    Ushijima I; Mizuki Y; Kobayashi T; Aoki T; Suetsugi M; Usami K; Watanabe Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Nov; 24(8):1369-77. PubMed ID: 11125860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats.
    Kosten TA
    Schizophr Bull; 1997; 23(2):203-13. PubMed ID: 9165631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral supersensitivity to methamphetamine following chronic treatment with (--)-sulpiride in the rat.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Boll Soc Ital Biol Sper; 1981 Feb; 57(4):401-6. PubMed ID: 7195265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
    Meller E; Friedman E
    Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats.
    Ellison G; Johansson P; Levin E; See R; Gunne L
    Psychopharmacology (Berl); 1988; 96(2):253-7. PubMed ID: 2906749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of mesolimbic behavioral supersensitivity by naloxone.
    Seeger TF; Nazzaro JM; Gardner EL
    Eur J Pharmacol; 1980 Aug; 65(4):435-8. PubMed ID: 7408948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diltiazem suppresses quinpirole-induced oral stereotypies in haloperidol withdrawn rats.
    Pucilowski O; Eichelman B
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):717-22. PubMed ID: 1683487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics.
    Halperin R; Guerin JJ; Davis KL
    Psychopharmacology (Berl); 1989; 98(3):386-91. PubMed ID: 2568659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential enhancement of locomotor activity by dopamine agonists following chronic neuroleptic treatment: an animal model of tardive dyskinesia.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Eur J Pharmacol; 1979 Apr; 55(1):103-7. PubMed ID: 35357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
    Biazzi A; Fregnan GB
    Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.